"Sometimes the juice ain't worth the squeeze... especially when combining grapefruit with medicines.
While it can be part of a balanced and nutritious diet, grapefruit can have serious consequences when taken with certain medications. Cu"...
Optimark Side Effects Center
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Optimark FDA Prescribing Information: Side Effects
A total of 1309 subjects (24 healthy volunteers and 1285 patients) received OptiMARK™ (gadoversetamide injection) Injection and 46 subjects received placebo (saline). Of the 1309 subjects who received OptiMARK™ (gadoversetamide injection) Injection, 680 (52%) were men and 629 (48%) were women with a mean age of 50 years (range 12 to 85 years). In this population there were 1102 (84%) white, 116 (9%) black, 33 (3%) Asian, and 58 (4%) subjects and patients of other racial groups.
In the clinical trials there were 8 serious adverse events and 1 death. The one death occurred in a patient with advanced multisystem disease and appeared to be related to the underlying disease. Six of the eight serious events appeared to be related to underlying disease. Two patients had either persistent paresthesia or numbness of unknown etiology that required hospitalization for diagnostic evaluations or treatment.
Of the 1309 subjects, 460 (35%) reported at least one adverse event out of a total of 997 adverse events; and 22 (47.8%) of the 46 subjects who received placebo reported at least one adverse event out of a total of 81 adverse events.
The most commonly noted adverse events were headache (9.4%), vasodilatation (6.4%), taste perversion (6.2%), dizziness (3.7%), nausea (3.2%), and paresthesia (2.2%). All adverse events reported in 1% or greater of all patients are listed in Table 5. Of the subjects and patients who experienced adverse events, 95.8% of the adverse events were of mild or moderate intensity after dosing with OptiMARK™ (gadoversetamide injection) Injection.
Table 5: Summary Adverse Events Experienced by ≥ 1% of
|Body System or Event Type||OptiMARK™ (N = 1309)|
|Number of patients with one or more adverse events||460 (35.1%)|
|Total Number of Adverse Events||997|
|Patients with any injection associated discomfort||345 (26.4%)|
|Body as a Whole||193 (14.7%)|
|Pain Abdomen||24 (1.8%)|
|Pain Back||16 (1.2%)|
|Injection Site||35 (2.7%)|
|Injection Site Reaction||20 (1.5%)|
|Nervous System||109 (8.3%)|
|Skin and Appendages||37 (2.8%)|
|Special Senses||96 (7.3%)|
|Taste Perversion||81 (6.2%)|
The following adverse reactions occurred in less than 1% of the patients:
Skin and Appendages: application site reaction, edema injection site, erythema multiforme, pruritus, rash macular-papular and vesicullous bullous, skin dry, thrombophlebitis, inflammation injection site, urticaria
Post-marketing surveillance reports have identified cases of seizure.
Read the entire FDA prescribing information for Optimark (Gadoversetamide Injection) »
Additional OptiMARK Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.